Patent: 8,895,010
✉ Email this page to a colleague
Summary for Patent: 8,895,010
| Title: | Antibody polypeptides that antagonize CD40L |
| Abstract: | Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single V.sub.H or V.sub.K domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen. |
| Inventor(s): | Nadler; Steven G. (Princeton, NJ), Tamura; James K. (Yardley, PA), Price; Laura (Langhorne, PA), Rehfuss; Robert P. (North Wales, PA), Suchard; Suzanne J. (Wilmington, DE), Suri; Anish (Yardley, PA), Bryson; James William (Langhorne, PA), Yamniuk; Aaron (Lawrenceville, NJ), Grant; Steven (Swaffham Prior, GB), Ignatovich; Olga (Cambridge, GB), Drew; Philip (Histon, GB) |
| Assignee: | Bristol-Myers Squibb Company (Princeton, NJ) Domantis Limited (Brentford, Middlesex, GB) |
| Application Number: | 13/650,493 |
| Patent Claims: | see list of patent claims |
Details for Patent 8,895,010
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Bristol-myers Squibb Company | NULOJIX | belatacept | For Injection | 125288 | 06/15/2011 | ⤷ Try a Trial | 2031-10-13 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
